

SPECTRUM PHARMACEUTICALS INC

Form 8-K

May 11, 2007

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 8-K**  
**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(D) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report: May 11, 2007**  
**Spectrum Pharmaceuticals, Inc.**  
(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-28782**  
(Commission File  
Number)

**93-0979187**  
(I.R.S. Employer  
Identification No.)

**157 Technology Drive**  
**Irvine, California**  
(Address of principal executive offices)

**92618**  
(Zip Code)

**(949) 788-6700**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01. Other Events.**

On May 11, 2007, Spectrum Pharmaceuticals, Inc. (the Company ) issued a press concerning the completion of the previously announced sale of 5,134,100 shares of common stock at a price of \$6.25 per share. The net proceeds to the Company from the offering, after placement agent fees and estimated expenses, are approximately \$30 million. The Company had approximately \$73 million in cash, cash equivalents and marketable securities and approximately 31 million shares of common stock issued and outstanding as of May 10, 2007 following the equity offering.

A copy of the press release is filed as Exhibit 99.1 to this report and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated May 11, 2007.

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SPECTRUM PHARMACEUTICALS, INC.

BY: /s/ SHYAM KUMARIA

Shyam Kumaria  
Vice President, Finance

Date: May 11, 2007

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit No.</b>		<b>Description</b>
99.1	Press release dated May 11, 2007.	4